Akebia Therapeutics, Inc. (AKBA) Financials
AKBA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 225.5 million | 252.7 million |
2023-12-31 | 241.7 million | 272.3 million |
2023-09-30 | 235.0 million | 274.4 million |
2023-06-30 | 253.7 million | 280.5 million |
AKBA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -19.4 million | 2.4 million |
2023-12-31 | -2.3 million | 1.5 million |
2023-09-30 | -7.2 million | 1.8 million |
2023-06-30 | 3.6 million | 3.5 million |
AKBA Net Income
No data available :(
AKBA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 42.0 million | - | 12.7 million |
2023-12-31 | 42.9 million | - | 13.4 million |
2023-09-30 | 46.5 million | - | 15.1 million |
2023-06-30 | 53.6 million | 19.2 million | 16.2 million |
AKBA Shares Outstanding
AKBA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | - | 9.4 million | 25.4 million | - |
2023-12-31 | - | 9.5 million | 854000 | 25.4 million |
2023-09-30 | - | 13.3 million | 22.7 million | 22.7 million |
2023-06-30 | - | 20.2 million | 27.0 million | 27.0 million |
AKBA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 32.6 million | 12.0 million |
2023-12-31 | 56.2 million | 19.1 million |
2023-09-30 | 42.0 million | 18.0 million |
2023-06-30 | 56.4 million | 17.3 million |
AKBA
Price: $1.03
52 week price:
Earnings Per Share: -0.28 USD
P/E Ratio: -5.32
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.3 million
Ebitda: -24.0 millionMarket Capitalization: 270.4 million